Immunovant Reports $97.2 Million Quarterly Loss and IMVT-1402 Trial Results
Immunovant reported a net loss of $97.2 million, or $0.47 per share, for the quarter ended September 30, 2026, versus a $126.5 million loss a year earlier. Cash and cash equivalents totaled $722.3 million at quarter-end. The company said IMVT-1402 600 mg met the primary endpoint.
Immunovant reported a net loss of $97.2 million, or $0.47 per share, for the quarter ended September 30, 2026, compared with a $126.5 million loss a year earlier. Cash and cash equivalents totaled $722.3 million at quarter-end. The company also reported that IMVT-1402 600 mg met the primary endpoin…